Dynamin	B:C0669938
-	I:C0669938
related	I:C0669938
protein	I:C0669938
1	I:C0669938
mediates	O
low	O
glucose	I:C0017725
-	O
induced	O
endothelial	O
dysfunction	I:C0856169
in	O
human	O
arterioles	O
.	O

Dynamin	O
-	I:C0669938
related	I:C0669938
protein	I:C0669938
1	I:C0669938
mediates	O
low	B:C0017725
glucose	I:C0017725
-	O
induced	O
endothelial	O
dysfunction	I:C0856169
in	O
human	O
arterioles	O
.	O

Dynamin	O
-	I:C0669938
related	I:C0669938
protein	I:C0669938
1	I:C0669938
mediates	O
low	O
glucose	I:C0017725
-	O
induced	O
endothelial	B:C0856169
dysfunction	I:C0856169
in	O
human	O
arterioles	O
.	O

Dynamin	O
-	I:C0669938
related	I:C0669938
protein	I:C0669938
1	I:C0669938
mediates	O
low	O
glucose	I:C0017725
-	O
induced	O
endothelial	O
dysfunction	I:C0856169
in	O
human	B:C0086418
arterioles	O
.	O

Dynamin	O
-	I:C0669938
related	I:C0669938
protein	I:C0669938
1	I:C0669938
mediates	O
low	O
glucose	I:C0017725
-	O
induced	O
endothelial	O
dysfunction	I:C0856169
in	O
human	O
arterioles	B:C0003847
.	O

Intensive	O
glycemic	B:C1327622
regulation	I:C1327622
has	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
hypoglycemia	O
.	O

Intensive	O
glycemic	O
regulation	I:C1327622
has	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
hypoglycemia	B:C0020615
.	O

Hypoglycemic	B:C0020615
burden	O
correlates	O
with	O
adverse	O
cardiovascular	O
complications	I:C0161816
and	O
contributes	O
acutely	O
and	O
chronically	O
to	O
endothelial	O
dysfunction	I:C0856169
.	O

Hypoglycemic	O
burden	O
correlates	O
with	O
adverse	O
cardiovascular	B:C0161816
complications	I:C0161816
and	O
contributes	O
acutely	O
and	O
chronically	O
to	O
endothelial	O
dysfunction	I:C0856169
.	O

Hypoglycemic	O
burden	O
correlates	O
with	O
adverse	O
cardiovascular	O
complications	I:C0161816
and	O
contributes	O
acutely	O
and	O
chronically	O
to	O
endothelial	B:C0856169
dysfunction	I:C0856169
.	O

Prior	O
data	O
indicate	O
that	O
mitochondrial	B:C4021734
dysfunction	I:C4021734
contributes	O
to	O
hypoglycemia	O
-	O
induced	O
endothelial	O
dysfunction	I:C0856169
,	O
but	O
the	O
mechanisms	O
behind	O
this	O
linkage	O
remain	O
unknown	O
.	O

Prior	O
data	O
indicate	O
that	O
mitochondrial	O
dysfunction	I:C4021734
contributes	O
to	O
hypoglycemia	B:C0020615
-	O
induced	O
endothelial	O
dysfunction	I:C0856169
,	O
but	O
the	O
mechanisms	O
behind	O
this	O
linkage	O
remain	O
unknown	O
.	O

Prior	O
data	O
indicate	O
that	O
mitochondrial	O
dysfunction	I:C4021734
contributes	O
to	O
hypoglycemia	O
-	O
induced	O
endothelial	B:C0856169
dysfunction	I:C0856169
,	O
but	O
the	O
mechanisms	O
behind	O
this	O
linkage	O
remain	O
unknown	O
.	O

We	O
attempt	O
to	O
determine	O
whether	O
clinically	O
relevant	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
(	O
low	O
-	I:C0017725
glucose	I:C0017725
)	O
exposures	O
acutely	O
induce	O
endothelial	O
dysfunction	I:C0856169
through	O
activation	O
of	O
the	O
mitochondrial	O
fission	I:C0230871
process	I:C0230871
.	O

We	O
attempt	O
to	O
determine	O
whether	O
clinically	O
relevant	O
low	O
-	I:C0017725
glucose	I:C0017725
(	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
)	O
exposures	O
acutely	O
induce	O
endothelial	O
dysfunction	I:C0856169
through	O
activation	O
of	O
the	O
mitochondrial	O
fission	I:C0230871
process	I:C0230871
.	O

We	O
attempt	O
to	O
determine	O
whether	O
clinically	O
relevant	O
low	O
-	I:C0017725
glucose	I:C0017725
(	O
low	O
-	I:C0017725
glucose	I:C0017725
)	O
exposures	O
acutely	O
induce	O
endothelial	B:C0856169
dysfunction	I:C0856169
through	O
activation	O
of	O
the	O
mitochondrial	O
fission	I:C0230871
process	I:C0230871
.	O

We	O
attempt	O
to	O
determine	O
whether	O
clinically	O
relevant	O
low	O
-	I:C0017725
glucose	I:C0017725
(	O
low	O
-	I:C0017725
glucose	I:C0017725
)	O
exposures	O
acutely	O
induce	O
endothelial	O
dysfunction	I:C0856169
through	O
activation	O
of	O
the	O
mitochondrial	B:C0230871
fission	I:C0230871
process	I:C0230871
.	O

Characterization	O
of	O
mitochondrial	B:C0243095
morphology	I:C0243095
was	O
carried	O
out	O
in	O
cultured	O
endothelial	O
cells	I:C0225336
by	O
using	O
confocal	O
microscopy	I:C0242842
.	O

Characterization	O
of	O
mitochondrial	O
morphology	I:C0243095
was	O
carried	O
out	O
in	O
cultured	O
endothelial	B:C0225336
cells	I:C0225336
by	O
using	O
confocal	O
microscopy	I:C0242842
.	O

Characterization	O
of	O
mitochondrial	O
morphology	I:C0243095
was	O
carried	O
out	O
in	O
cultured	O
endothelial	O
cells	I:C0225336
by	O
using	O
confocal	B:C0242842
microscopy	I:C0242842
.	O

Isolated	O
human	B:C0086418
arterioles	O
were	O
used	O
to	O
explore	O
the	O
effect	O
low	O
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
mitochondrial	O
fission	I:C0230871
has	O
on	O
the	O
formation	O
of	O
detrimental	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
bioavailability	O
of	O
nitric	O
oxide	I:C0028128
(	O
nitric	O
oxide	I:C0028128
)	O
,	O
and	O
endothelial	O
-	I:C1258036
dependent	I:C1258036
vascular	I:C1258036
relaxation	I:C1258036
.	O

Isolated	O
human	O
arterioles	B:C0003847
were	O
used	O
to	O
explore	O
the	O
effect	O
low	O
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
mitochondrial	O
fission	I:C0230871
has	O
on	O
the	O
formation	O
of	O
detrimental	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
bioavailability	O
of	O
nitric	O
oxide	I:C0028128
(	O
nitric	O
oxide	I:C0028128
)	O
,	O
and	O
endothelial	O
-	I:C1258036
dependent	I:C1258036
vascular	I:C1258036
relaxation	I:C1258036
.	O

Isolated	O
human	O
arterioles	O
were	O
used	O
to	O
explore	O
the	O
effect	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
mitochondrial	O
fission	I:C0230871
has	O
on	O
the	O
formation	O
of	O
detrimental	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
bioavailability	O
of	O
nitric	O
oxide	I:C0028128
(	O
nitric	O
oxide	I:C0028128
)	O
,	O
and	O
endothelial	O
-	I:C1258036
dependent	I:C1258036
vascular	I:C1258036
relaxation	I:C1258036
.	O

Isolated	O
human	O
arterioles	O
were	O
used	O
to	O
explore	O
the	O
effect	O
low	O
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
mitochondrial	B:C0230871
fission	I:C0230871
has	O
on	O
the	O
formation	O
of	O
detrimental	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
bioavailability	O
of	O
nitric	O
oxide	I:C0028128
(	O
nitric	O
oxide	I:C0028128
)	O
,	O
and	O
endothelial	O
-	I:C1258036
dependent	I:C1258036
vascular	I:C1258036
relaxation	I:C1258036
.	O

Isolated	O
human	O
arterioles	O
were	O
used	O
to	O
explore	O
the	O
effect	O
low	O
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
mitochondrial	O
fission	I:C0230871
has	O
on	O
the	O
formation	O
of	O
detrimental	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
bioavailability	O
of	O
nitric	B:C0028128
oxide	I:C0028128
(	O
nitric	O
oxide	I:C0028128
)	O
,	O
and	O
endothelial	O
-	I:C1258036
dependent	I:C1258036
vascular	I:C1258036
relaxation	I:C1258036
.	O

Isolated	O
human	O
arterioles	O
were	O
used	O
to	O
explore	O
the	O
effect	O
low	O
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
mitochondrial	O
fission	I:C0230871
has	O
on	O
the	O
formation	O
of	O
detrimental	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
bioavailability	O
of	O
nitric	O
oxide	I:C0028128
(	O
nitric	B:C0028128
oxide	I:C0028128
)	O
,	O
and	O
endothelial	O
-	I:C1258036
dependent	I:C1258036
vascular	I:C1258036
relaxation	I:C1258036
.	O

Isolated	O
human	O
arterioles	O
were	O
used	O
to	O
explore	O
the	O
effect	O
low	O
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
mitochondrial	O
fission	I:C0230871
has	O
on	O
the	O
formation	O
of	O
detrimental	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
bioavailability	O
of	O
nitric	O
oxide	I:C0028128
(	O
nitric	O
oxide	I:C0028128
)	O
,	O
and	O
endothelial	B:C1258036
-	I:C1258036
dependent	I:C1258036
vascular	I:C1258036
relaxation	I:C1258036
.	O

Fluorescence	B:C0026022
microscopy	I:C0026022
was	O
employed	O
to	O
visualize	O
changes	O
in	O
mitochondrial	O
ROS	O
and	O
nitric	O
oxide	I:C0028128
levels	O
and	O
videomicroscopy	O
applied	O
to	O
measure	O
vasodilation	O
response	O
.	O

Fluorescence	O
microscopy	I:C0026022
was	O
employed	O
to	O
visualize	O
changes	O
in	O
mitochondrial	B:C0026237
ROS	O
and	O
nitric	O
oxide	I:C0028128
levels	O
and	O
videomicroscopy	O
applied	O
to	O
measure	O
vasodilation	O
response	O
.	O

Fluorescence	O
microscopy	I:C0026022
was	O
employed	O
to	O
visualize	O
changes	O
in	O
mitochondrial	O
ROS	O
and	O
nitric	B:C0028128
oxide	I:C0028128
levels	O
and	O
videomicroscopy	O
applied	O
to	O
measure	O
vasodilation	O
response	O
.	O

Fluorescence	O
microscopy	I:C0026022
was	O
employed	O
to	O
visualize	O
changes	O
in	O
mitochondrial	O
ROS	O
and	O
nitric	O
oxide	I:C0028128
levels	O
and	O
videomicroscopy	B:C0242940
applied	O
to	O
measure	O
vasodilation	O
response	O
.	O

Fluorescence	O
microscopy	I:C0026022
was	O
employed	O
to	O
visualize	O
changes	O
in	O
mitochondrial	O
ROS	O
and	O
nitric	O
oxide	I:C0028128
levels	O
and	O
videomicroscopy	O
applied	O
to	O
measure	O
vasodilation	B:C0042401
response	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	B:C0033684
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	B:C0669938
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	B:C2933581
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	B:C0230871
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	B:C1257792
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	B:C2933581
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	B:C0005847
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	B:C2933581
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	B:C0150312
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	B:C0028128
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	B:C2933581
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	B:C0184511
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	B:C0042401
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	B:C0001041
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	I:C0033684
Drp1	O
with	O
Mdivi	O
-	I:C2933581
1	I:C2933581
during	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
reduced	O
mitochondrial	O
fragmentation	I:C0230871
among	O
vascular	O
endothelial	I:C1257792
cells	I:C1257792
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
0.469	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
2.036	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
nitric	O
oxide	I:C0028128
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
1.352	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	O
-	I:C2933581
1	I:C2933581
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	I:C0042401
response	O
to	O
acetylcholine	O
(	O
low	O
-	I:C0017725
glucose	I:C0017725
:	O
31.6	O
%	O
;	O
low	O
-	I:C0017725
glucose	I:C0017725
+	O
Mdivi	B:C2933581
-	I:C2933581
1	I:C2933581
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Additionally	O
,	O
decreased	O
expression	B:C1171362
of	O
Drp1	O
via	O
siRNA	O
knockdown	O
during	O
low	O
-	I:C0017725
glucose	I:C0017725
conditions	O
also	O
improved	O
vascular	O
relaxation	I:C1258036
.	O

Additionally	O
,	O
decreased	O
expression	O
of	O
Drp1	B:C0669938
via	O
siRNA	O
knockdown	O
during	O
low	O
-	I:C0017725
glucose	I:C0017725
conditions	O
also	O
improved	O
vascular	O
relaxation	I:C1258036
.	O

Additionally	O
,	O
decreased	O
expression	O
of	O
Drp1	O
via	O
siRNA	B:C1099354
knockdown	O
during	O
low	O
-	I:C0017725
glucose	I:C0017725
conditions	O
also	O
improved	O
vascular	O
relaxation	I:C1258036
.	O

Additionally	O
,	O
decreased	O
expression	O
of	O
Drp1	O
via	O
siRNA	O
knockdown	B:C2350567
during	O
low	O
-	I:C0017725
glucose	I:C0017725
conditions	O
also	O
improved	O
vascular	O
relaxation	I:C1258036
.	O

Additionally	O
,	O
decreased	O
expression	O
of	O
Drp1	O
via	O
siRNA	O
knockdown	O
during	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
conditions	O
also	O
improved	O
vascular	O
relaxation	I:C1258036
.	O

Additionally	O
,	O
decreased	O
expression	O
of	O
Drp1	O
via	O
siRNA	O
knockdown	O
during	O
low	O
-	I:C0017725
glucose	I:C0017725
conditions	O
also	O
improved	B:C0184511
vascular	O
relaxation	I:C1258036
.	O

Additionally	O
,	O
decreased	O
expression	O
of	O
Drp1	O
via	O
siRNA	O
knockdown	O
during	O
low	O
-	I:C0017725
glucose	I:C0017725
conditions	O
also	O
improved	O
vascular	B:C1258036
relaxation	I:C1258036
.	O

Exposure	O
to	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
imparts	O
endothelial	O
dysfunction	I:C0856169
coupled	O
with	O
altered	O
mitochondrial	O
phenotypes	O
among	O
isolated	O
human	O
arterioles	O
.	O

Exposure	O
to	O
low	O
-	I:C0017725
glucose	I:C0017725
imparts	O
endothelial	B:C0856169
dysfunction	I:C0856169
coupled	O
with	O
altered	O
mitochondrial	O
phenotypes	O
among	O
isolated	O
human	O
arterioles	O
.	O

Exposure	O
to	O
low	O
-	I:C0017725
glucose	I:C0017725
imparts	O
endothelial	O
dysfunction	I:C0856169
coupled	O
with	O
altered	O
mitochondrial	B:C0026237
phenotypes	O
among	O
isolated	O
human	O
arterioles	O
.	O

Exposure	O
to	O
low	O
-	I:C0017725
glucose	I:C0017725
imparts	O
endothelial	O
dysfunction	I:C0856169
coupled	O
with	O
altered	O
mitochondrial	O
phenotypes	O
among	O
isolated	O
human	B:C0086418
arterioles	O
.	O

Exposure	O
to	O
low	O
-	I:C0017725
glucose	I:C0017725
imparts	O
endothelial	O
dysfunction	I:C0856169
coupled	O
with	O
altered	O
mitochondrial	O
phenotypes	O
among	O
isolated	O
human	O
arterioles	B:C0003847
.	O

Disruption	O
of	O
Drp1	B:C0669938
and	O
subsequent	O
mitochondrial	O
fragmentation	I:C0230871
events	O
prevents	O
impaired	O
vascular	O
dilation	I:C0042401
,	O
restores	O
mitochondrial	O
phenotype	O
,	O
and	O
implicates	O
mitochondrial	O
fission	I:C0230871
as	O
a	O
primary	O
mediator	O
of	O
low	O
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
endothelial	O
dysfunction	I:C0856169
.	O

Disruption	O
of	O
Drp1	O
and	O
subsequent	O
mitochondrial	B:C0230871
fragmentation	I:C0230871
events	O
prevents	O
impaired	O
vascular	O
dilation	I:C0042401
,	O
restores	O
mitochondrial	O
phenotype	O
,	O
and	O
implicates	O
mitochondrial	O
fission	I:C0230871
as	O
a	O
primary	O
mediator	O
of	O
low	O
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
endothelial	O
dysfunction	I:C0856169
.	O

Disruption	O
of	O
Drp1	O
and	O
subsequent	O
mitochondrial	O
fragmentation	I:C0230871
events	O
prevents	O
impaired	O
vascular	B:C0042401
dilation	I:C0042401
,	O
restores	O
mitochondrial	O
phenotype	O
,	O
and	O
implicates	O
mitochondrial	O
fission	I:C0230871
as	O
a	O
primary	O
mediator	O
of	O
low	O
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
endothelial	O
dysfunction	I:C0856169
.	O

Disruption	O
of	O
Drp1	O
and	O
subsequent	O
mitochondrial	O
fragmentation	I:C0230871
events	O
prevents	O
impaired	O
vascular	O
dilation	I:C0042401
,	O
restores	O
mitochondrial	B:C0026237
phenotype	O
,	O
and	O
implicates	O
mitochondrial	O
fission	I:C0230871
as	O
a	O
primary	O
mediator	O
of	O
low	O
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
endothelial	O
dysfunction	I:C0856169
.	O

Disruption	O
of	O
Drp1	O
and	O
subsequent	O
mitochondrial	O
fragmentation	I:C0230871
events	O
prevents	O
impaired	O
vascular	O
dilation	I:C0042401
,	O
restores	O
mitochondrial	O
phenotype	O
,	O
and	O
implicates	O
mitochondrial	B:C0230871
fission	I:C0230871
as	O
a	O
primary	O
mediator	O
of	O
low	O
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
endothelial	O
dysfunction	I:C0856169
.	O

Disruption	O
of	O
Drp1	O
and	O
subsequent	O
mitochondrial	O
fragmentation	I:C0230871
events	O
prevents	O
impaired	O
vascular	O
dilation	I:C0042401
,	O
restores	O
mitochondrial	O
phenotype	O
,	O
and	O
implicates	O
mitochondrial	O
fission	I:C0230871
as	O
a	O
primary	O
mediator	O
of	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
endothelial	O
dysfunction	I:C0856169
.	O

Disruption	O
of	O
Drp1	O
and	O
subsequent	O
mitochondrial	O
fragmentation	I:C0230871
events	O
prevents	O
impaired	O
vascular	O
dilation	I:C0042401
,	O
restores	O
mitochondrial	O
phenotype	O
,	O
and	O
implicates	O
mitochondrial	O
fission	I:C0230871
as	O
a	O
primary	O
mediator	O
of	O
low	O
-	I:C0017725
glucose	I:C0017725
-	O
induced	O
endothelial	B:C0856169
dysfunction	I:C0856169
.	O

Acute	O
low	B:C0017725
-	I:C0017725
glucose	I:C0017725
exposure	O
induces	O
mitochondrial	O
fragmentation	I:C0230871
in	O
endothelial	O
cells	I:C0225336
via	O
Drp1	O
and	O
is	O
associated	O
with	O
impaired	O
endothelial	O
function	O
in	O
human	O
arterioles	O
.	O

Acute	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
induces	O
mitochondrial	B:C0230871
fragmentation	I:C0230871
in	O
endothelial	O
cells	I:C0225336
via	O
Drp1	O
and	O
is	O
associated	O
with	O
impaired	O
endothelial	O
function	O
in	O
human	O
arterioles	O
.	O

Acute	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
induces	O
mitochondrial	O
fragmentation	I:C0230871
in	O
endothelial	B:C0225336
cells	I:C0225336
via	O
Drp1	O
and	O
is	O
associated	O
with	O
impaired	O
endothelial	O
function	O
in	O
human	O
arterioles	O
.	O

Acute	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
induces	O
mitochondrial	O
fragmentation	I:C0230871
in	O
endothelial	O
cells	I:C0225336
via	O
Drp1	B:C0669938
and	O
is	O
associated	O
with	O
impaired	O
endothelial	O
function	O
in	O
human	O
arterioles	O
.	O

Acute	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
induces	O
mitochondrial	O
fragmentation	I:C0230871
in	O
endothelial	O
cells	I:C0225336
via	O
Drp1	O
and	O
is	O
associated	O
with	O
impaired	O
endothelial	B:C0225336
function	O
in	O
human	O
arterioles	O
.	O

Acute	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
induces	O
mitochondrial	O
fragmentation	I:C0230871
in	O
endothelial	O
cells	I:C0225336
via	O
Drp1	O
and	O
is	O
associated	O
with	O
impaired	O
endothelial	O
function	B:C0007613
in	O
human	O
arterioles	O
.	O

Acute	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
induces	O
mitochondrial	O
fragmentation	I:C0230871
in	O
endothelial	O
cells	I:C0225336
via	O
Drp1	O
and	O
is	O
associated	O
with	O
impaired	O
endothelial	O
function	O
in	O
human	B:C0086418
arterioles	O
.	O

Acute	O
low	O
-	I:C0017725
glucose	I:C0017725
exposure	O
induces	O
mitochondrial	O
fragmentation	I:C0230871
in	O
endothelial	O
cells	I:C0225336
via	O
Drp1	O
and	O
is	O
associated	O
with	O
impaired	O
endothelial	O
function	O
in	O
human	O
arterioles	B:C0003847
.	O

Targeting	B:C0599894
of	O
Drp1	O
prevents	O
fragmentation	O
,	O
improves	O
vasofunction	O
,	O
and	O
may	O
provide	O
a	O
therapeutic	O
target	O
for	O
improving	O
cardiovascular	O
complications	I:C0161816
among	O
diabetics	O
.	O

Targeting	O
of	O
Drp1	B:C0669938
prevents	O
fragmentation	O
,	O
improves	O
vasofunction	O
,	O
and	O
may	O
provide	O
a	O
therapeutic	O
target	O
for	O
improving	O
cardiovascular	O
complications	I:C0161816
among	O
diabetics	O
.	O

Targeting	O
of	O
Drp1	O
prevents	O
fragmentation	B:C0230871
,	O
improves	O
vasofunction	O
,	O
and	O
may	O
provide	O
a	O
therapeutic	O
target	O
for	O
improving	O
cardiovascular	O
complications	I:C0161816
among	O
diabetics	O
.	O

Targeting	O
of	O
Drp1	O
prevents	O
fragmentation	O
,	O
improves	O
vasofunction	O
,	O
and	O
may	O
provide	O
a	O
therapeutic	O
target	O
for	O
improving	O
cardiovascular	B:C0161816
complications	I:C0161816
among	O
diabetics	O
.	O

Targeting	O
of	O
Drp1	O
prevents	O
fragmentation	O
,	O
improves	O
vasofunction	O
,	O
and	O
may	O
provide	O
a	O
therapeutic	O
target	O
for	O
improving	O
cardiovascular	O
complications	I:C0161816
among	O
diabetics	B:C0241863
.	O

Listen	O
to	O
this	O
article	O
's	O
corresponding	O
podcast	O
@	O
http://ajpheart.podbean.com/e/mitochondrial-dynamics-impact-endothelial-function/.	B:C1704666

